TY  - JOUR
AU  - Pérez-García, José Manuel
AU  - Gebhart, Geraldine
AU  - Borrego, Manuel Ruiz
AU  - Schmid, Peter
AU  - Marmé, Frederik
AU  - Prat, Aleix
AU  - Dalenc, Florence
AU  - Kerrou, Khaldoun
AU  - Colleoni, Marco
AU  - Braga, Sofía
AU  - Malfettone, Andrea
AU  - Sampayo-Cordero, Miguel
AU  - Cortés, Javier
AU  - Llombart-Cussac, Antonio
PY  - 2022
DO  - 10.2217/fon-2022-0663
UR  - http://hdl.handle.net/10668/20495
T2  - Future oncology (London, England)
AB  - This is a summary of a publication about the PHERGain study, which was published in The Lancet Oncology in May 2021. The study includes 376 women with a type of breast cancer called HER2-positive breast cancer that can be removed by surgery. In the...
LA  - en
KW  - FDG-PET
KW  - HER2-positive
KW  - de-escalation
KW  - early breast cancer
KW  - pathologic complete response
KW  - pertuzumab
KW  - trastuzumab
KW  - Humans
KW  - Female
KW  - Trastuzumab
KW  - Breast Neoplasms
KW  - Fluorodeoxyglucose F18
KW  - Quality of Life
KW  - Receptor, ErbB-2
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Neoadjuvant Therapy
TI  - Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.
TY  - research article
VL  - 18
ER  -